How Jevtana May Help

JEVTANA helped men live longer and shrunk tumors after docetaxel

The effectiveness of JEVTANA was proven in a clinical study of 755 men who:

  • Had prostate cancer that spread to other parts of the body
  • Were no longer responding to medical or surgical treatment to lower testosterone
  • Had previously received treatment with docetaxel, a type of anti-cancer infusion medicine

In the clinical study,
JEVTANA improved overall survival in men:

Reduced risk of death 30%

vs mitoxantrone The number of deaths were 234 (62%) out of 378 men with JEVTANA and 279 (74%) out of 377 men with mitoxantrone.

Prolonged median overall survival to 15.1 months

vs 12.7 months with mitoxantrone

Shrunk tumors in 3X more men

14.4% vs. 4.4% with mitoxantrone

The effectiveness of JEVTANA was also proven in a clinical study of 1,200 men looking at the risk and benefits of two different dosing options: 20 mg/m2 versus 25 mg/m2.

Please talk to your healthcare provider to learn more.


The median overall survival is the length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that half of the patients in a group of patients diagnosed with the disease are still alive. (NCI Dictionary of Cancer Terms. National Cancer Institute at the National Institutes of Health website. www.cancer.gov/dictionary. Accessed November 1, 2016.)

Did you know?

In the study, JEVTANA was compared to an active anti-cancer treatment called mitoxantrone. This is different from a placebo-controlled study, where one treatment is compared with placebo — a substance or treatment with no active therapeutic effect.